Thursday, November 18, 2010

FDA Approves Amgen's XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors

First Bone Targeted Therapy for Cancer Patients to Be Approved in Nearly a Decade

Approval Based on Largest Clinical Program Ever Conducted in Patients with Bone Metastases

THOUSAND OAKS, Calif., Nov. 18, 2010 /PRNewswire via COMTEX/—Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved XGEVA(TM) (denosumab), the first and only RANK Ligand inhibitorfor the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. XGEVA was approved following a 6 month priority review by the FDA, a designation reserved for drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma.

Read the rest of this entry

Posted in Press Releases

Wednesday, November 17, 2010

Amgen Foundation and Ashoka's Changemakers Announce Finalists in Patients | Choices | Empowerment Competition

Voting Starts Today

THOUSAND OAKS, Calif. and WASHINGTON, Nov. 17, 2010 /PRNewswire via COMTEX/ —The Amgen Foundation and Ashoka’s Changemakers today announced ten finalists in the Patients | Choices | Empowerment competition and launched public online voting in search of the best innovative solutions that empower patients, elevate patients’ voices, and improve health outcomes.

Read the rest of this entry

Posted in Press Releases

Tuesday, November 16, 2010

Call for Applications: The Amgen Award for Science Teaching Excellence

34 Outstanding Teachers Will Be Recognized in Communities Where Amgen Operates

THOUSAND OAKS, Calif., Nov. 16, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced that it now invites applications for its 19th annual Amgen Award for Science Teaching Excellence (AASTE). This award is designed to recognize and honor extraordinary science teachers at the K-12 level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in student learning in communities where Amgen operates.

Read the rest of this entry

Posted in Press Releases

Thursday, November 11, 2010

Amgen Foundation Recognizes Outstanding Staff Volunteers and Contributes $55,000 to Their Favorite Local Nonprofits

THOUSAND OAKS, Calif., Nov. 11, 2010 /PRNewswire via COMTEX/—Amgen today announced the 11 recipients of the Amgen Excellence in Volunteering Awards. Launched this year by the Amgen Foundation, the Awards recognize staff in the United States (U.S.) and Puerto Rico who are making a difference in the communities where the company has a presence. The Amgen Foundation will award $5,000 to each nonprofit organization featured in the winning staff members’ applications.

Read the rest of this entry

Posted in Press Releases

Wednesday, November 10, 2010

Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP

THOUSAND OAKS, Calif., Nov. 10, 2010 /PRNewswire via COMTEX/—Amgen Inc. (Nasdaq: AMGN) today announced the publication of results from the first open-label study to compare Nplate® (romiplostim) treatment to standard of care therapies (SOC) in non-splenectomized adult patients with chronic immune thrombocytopenia (ITP). The study results, which were published today in the New England Journal of Medicine (NEJM), show that both the incidence of treatment failure and need for splenectomy were reduced among the Nplate-treated patients. Data also showed that patients receiving SOC therapies required splenectomies earlier when compared with patients treated with Nplate. Additionally, patients in the Nplate group experienced increased platelet counts, higher platelet response rates, less bleeding, and fewer blood transfusions compared to patients in the SOC group. Adverse events associated with Nplate treatment were similar to those in previous studies, were generally mild or moderate in severity, and did not result in treatment discontinuation. Headache and fatigue were the most commonly reported adverse events.

Read the rest of this entry

Posted in Press Releases